4SC to present at upcoming scientific conferences
Planegg-Martinsried, Germany, 31 August 2017 – 4SC AG (4SC, FSE Prime Standard: VSC) today announced that 4SC will be attending several upcoming scientific conferences. All posters and presentations will be available for download at 4SC’s website after the respective conferences.
4SC’s attendees will be available for one-on-one meetings.
8 to 12 September 2017
Madrid, Spain
Frank Hermann, M.D., Chief Development Officer
René Bartz, Ph.D., Product Manager (4SC-202)
| Poster | 1192P
4SC-202 plus anti-PD1: Breaking PD1-refractoriness to increase efficacy of checkpoint inhibition in patients with advanced-stage melanoma |
| Time | 10 September 2017, 1:15 p.m. |
| Location | Hall 8, Poster Display Session |
11th Annual Next-Generation Histone Deacetylase Inhibitors
27 to 28 September 2017
Boston, MA, USA
Svetlana Hamm, Ph.D., Head of Translational Pharmacology
| Presentation | Epigenetic Priming with New HDAC Class I Inhibitor 4SC-202 Sensitizes Tumor for Anti-PD-1/PD-L1 Therapy |
| Time | 28 September 2017, 9:35 a.m. |
3rd Annual Epigenetics Discovery Meeting
12 to 13 October
London, United Kingdom
René Bartz, Ph.D., Product Manager (4SC-202)
| Presentation | Modulation of the tumor microenvironment by epigenetic intervention |
| Time | 12 October 2017, 9:50 a.m. |
EORTC CLTF Meeting | Cutaneous Lymphomas: Insights & Therapeutic Progress 2017 Meeting
13 to 15 October 2017
London, United Kingdom
Susanne Danhauser-Riedl, M.D., Chief Medical Officer
Matthias Borgmann, Ph.D., Product Manager (Resminostat)
| 2 Posters | Resminostat’s action in CTCL – hints from a genome-wide study
A multicentre, double blind, randomised, placebo controlled, Phase II trial to evaluate Resminostat for maintenance treatment of patients with advanced stage (Stage IIB IVB) mycosis fungoides (MF) or Sézary Syndrome (SS) that have achieved disease control with systemic therapy – the RESMAIN Study |
| Time | Poster Session, 15 October 2017, 9:00 to 10:15 a.m. |
About resminostat
Resminostat is orally administered and potentially offers a novel approach to treating a wide variety of cancers, both as monotherapy and in combination therapy with other anti-cancer drugs. Resminostat inhibits tumor growth and proliferation, causes tumor regression, and strengthens the body’s own immune response to cancer.
Resminostat has been shown to be well tolerated in patients with advanced cancers in Phase I studies. Its use in the treatment of cutaneous T-cell lymphoma (CTCL), Hodgkin’s lymphoma and liver, lung, colon, pancreatic and biliary tract cancers has been and is being investigated in further clinical studies. Initial positive efficacy results for resminostat in monotherapy were observed in patients with Hodgkin’s lymphoma and in combination with sorafenib in selected patients with advanced liver cancer (hepatocellular cancer, HCC).
About 4SC-202
4SC-202 is an orally administered small molecule for the treatment of cancer with a unique mode of action that inhibits both class I histone deacetylase proteins and the lysine-specific demethylase protein, which play significant roles in the regulation of signaling pathways in cancer cells.
4SC-202 has been investigated in a Phase I study with 24 mostly heavily pretreated patients with several types of highly advanced hematologic cancers, and has proven to be tolerated. Positive signs of anti-tumor efficacy were observed with one complete remission for 28 months and one partial responder for 8 months.
Data from preclinical investigations demonstrated that 4SC-202 strengthens the anti-tumor immune response, alters the tumor microenvironment and increases infiltration of immune cells into the tumor. Further preclinical investigations showed that the combination of 4SC-202 with checkpoint inhibitors resulted in better anti-tumor activity than treatment with checkpoint inhibitors alone, suggesting a very promising clinical development path for 4SC-202 in both refractory and non-responding patients to treatment with checkpoint inhibitors.
About 4SC
4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life. 4SC’s pipeline is protected by a comprehensive portfolio of patents and comprises promising products that are in various stages of preclinical and clinical development. 4SC’s core assets include resminostat, 4SC-202 and 4SC-208.
4SC’s aim is to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. Founded in 1997, 4SC had 45 employees as of 12 June 2017. 4SC has been listed on the Prime Standard of the Frankfurt Stock Exchange since December 2005.
Forward-looking information
Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.